American Journal of Cardiovascular Drugs最新文献

{"title":"Risk of Hematuria, Proteinuria, and Cardiovascular Events in Patients Treated with Rosuvastatin Compared with Atorvastatin: A Retrospective Cohort Study in 136,680 Patients","authors":"Serena Ghanshani,&nbsp;Derek Antoku,&nbsp;AnMarie Nguyen,&nbsp;Yi-lin Wu,&nbsp;Ming-Sum Lee","doi":"10.1007/s40256-025-00776-3","DOIUrl":"10.1007/s40256-025-00776-3","url":null,"abstract":"<div><h3>Background</h3><p>Rosuvastatin and atorvastatin are the two primary high-intensity statins used for cardiovascular risk reduction. However, concerns have been raised regarding the renal safety profile of rosuvastatin. This study compared risks of hematuria, proteinuria, and cardiovascular events between rosuvastatin- and atorvastatin-treated patients.</p><h3>Methods</h3><p>This is a retrospective cohort study of atorvastatin and rosuvastatin users from 1 January 2018 to 31 December 2021. Inverse probability of treatment weighting was used to mitigate confounding. Poisson regression models were used to estimate adjusted relative risks.</p><h3>Results</h3><p>Of 136,680 patients (median age 61 years, 42.6% female), 46,292 were treated with atorvastatin and 90,388 rosuvastatin. During follow-up, there were 619 cases of proteinuria, 1843 cases of hematuria, and 19 cases of end-stage renal disease. Compared with atorvastatin, rosuvastatin was associated with a nonsignificant increase in the risk of hematuria (adjusted risk ratio [aRR] 1.1, 95% confidence interval [CI] 0.98–1.24) and proteinuria (aRR 1.02, 95% CI 0.83–1.25). Risk of cardiovascular events was significantly lower with rosuvastatin (aRR 0.77, 95% CI 0.70–0.83). Rosuvastatin was associated with a lower risk of myocardial infarction (aRR 0.75, 95% CI 0.63–0.91) and stroke (aRR 0.76, 95% CI 0.62–0.94) but not heart failure (aRR 0.82, 95% CI 0.63–1.06). Significant cardiovascular risk reduction was observed with rosuvastatin in the first 6 months.</p><h3>Conclusions and Relevance</h3><p>Compared with atorvastatin, rosuvastatin was associated with a significantly lower risk of cardiovascular events and a nonsignificant increase in hematuria and proteinuria. Overall, the cardiovascular benefits of rosuvastatin appear to outweigh the minor renal risks.</p></div>","PeriodicalId":7652,"journal":{"name":"American Journal of Cardiovascular Drugs","volume":"26 2","pages":"215 - 223"},"PeriodicalIF":3.0,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145436643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acknowledgement to Referees","authors":"","doi":"10.1007/s40256-025-00773-6","DOIUrl":"10.1007/s40256-025-00773-6","url":null,"abstract":"","PeriodicalId":7652,"journal":{"name":"American Journal of Cardiovascular Drugs","volume":"25 6","pages":"731 - 734"},"PeriodicalIF":3.0,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145436582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iron Deficiency as a Modifiable Risk Factor in Heart Failure: Evidence and Recommendations","authors":"Maryam,&nbsp;Treesa P. Varghese,&nbsp;B. Tazneem","doi":"10.1007/s40256-025-00771-8","DOIUrl":"10.1007/s40256-025-00771-8","url":null,"abstract":"<div><p>Heart failure (HF) is a chronic and progressive condition associated with significant morbidity and mortality and reduced quality of life. Among the various comorbidities that exacerbate HF outcomes, iron deficiency (ID) is increasingly recognized as a modifiable risk factor that contributes to decreased exercise capacity, fatigue, and hospitalizations, even in the absence of anemia. Approximately 30–50% of patients with HF present with ID, highlighting the need for routine screening and targeted management. The objective of this review was to summarize the pathophysiological basis, diagnostic criteria, and clinical implications of ID in HF and to provide evidence-based recommendations for its treatment based on current guidelines and clinical trials. Key clinical trials such as FAIR-HF, CONFIRM-HF, and AFFIRM-AHF have demonstrated that intravenous iron supplementation, particularly with ferric carboxymaltose, improves functional status, symptoms, and quality of life in patients with HF and ID. These benefits are observed irrespective of the presence of anemia, and treatment is associated with a favorable safety profile. Current guidelines recommend routine screening for ID in patients with chronic HF and consideration of intravenous iron supplementation in symptomatic patients with confirmed deficiency. Oral iron has shown limited efficacy in this population. In conclusion, ID is a treatable and impactful comorbidity in HF. Early detection and appropriate intravenous iron therapy can significantly improve patient-centered outcomes and should be incorporated into standard HF management strategies.</p></div>","PeriodicalId":7652,"journal":{"name":"American Journal of Cardiovascular Drugs","volume":"26 2","pages":"165 - 177"},"PeriodicalIF":3.0,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145385811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Midodrine to Facilitate Guideline-Directed Medical Therapy in Heart Failure with Reduced Ejection Fraction: A Promising Breakthrough or Just a False Hope?","authors":"Muhammad Sanusi,&nbsp;Andrew Ndakotsu,&nbsp;Dinakaran Umashankar,&nbsp;Prami Nakarmi,&nbsp;Roopeessh Vempati,&nbsp;Ravi Patel,&nbsp;Yash Varma,&nbsp;Yusuf Kamran Qadeer,&nbsp;Utheja Dasari,&nbsp;Geetha Krishnamoorthy","doi":"10.1007/s40256-025-00772-7","DOIUrl":"10.1007/s40256-025-00772-7","url":null,"abstract":"<p>Guideline-directed medical therapy (GDMT) is the foundation of managing heart failure with reduced ejection fraction (HFrEF). However, hypotension often limits its implementation, preventing optimal medication titration. Midodrine, an alpha-1 adrenergic agonist, has been explored as a potential option to facilitate the initiation and continuation of GDMT. Our review assesses the role of midodrine in the management of HFrEF, evaluating its benefits, risks, and clinical applicability. While emerging evidence suggests midodrine may help stabilize blood pressure and enable the optimization of GDMT in select patients with refractory hypotension, concerns remain regarding its long-term safety, potential for increased afterload, and associated mortality risks. Some observational studies indicate improved adherence to GDMT, but conflicting findings on patient outcomes, including increased mortality, highlight concerns. Still, the therapeutic promise of midodrine in HFrEF is undeniably compelling, offering the exciting possibility of transforming HFrEF management. The current evidence is low due to reliance on observational studies. Robust, large-scale randomized controlled trials are urgently needed to confirm its safety, efficacy, and precise patient selection criteria. The ongoing MIDOH-HF-P trial, results of which are anticipated in 2026, could provide vital insights into short-term benefits with GDMT. However, until robust evidence emerges and additional data are available, clinicians must exercise extreme caution when considering its off-label use.</p>","PeriodicalId":7652,"journal":{"name":"American Journal of Cardiovascular Drugs","volume":"26 2","pages":"127 - 135"},"PeriodicalIF":3.0,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145290786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: \"A Retrospective Cohort Study on Long‑Term Outcomes of Ticagrelor Versus Clopidogrel After Retrograde Percutaneous Coronary Intervention for Chronic Total Occlusion\"","authors":"Na Li,&nbsp;Yan Zhang,&nbsp;Mingjie Pang","doi":"10.1007/s40256-025-00768-3","DOIUrl":"10.1007/s40256-025-00768-3","url":null,"abstract":"","PeriodicalId":7652,"journal":{"name":"American Journal of Cardiovascular Drugs","volume":"26 1","pages":"121 - 122"},"PeriodicalIF":3.0,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145231385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early SGLT2i Therapy Facilitates In-Hospital ARNI Introduction Improving 6-Month Systolic Function in Patients with HFrEF","authors":"Andrea D’Amato,&nbsp;Silvia Prosperi,&nbsp;Federico Ferranti,&nbsp;Claudia Cestiè,&nbsp;Vincenzo Myftari,&nbsp;Rosanna Germanò,&nbsp;Camilla Segato,&nbsp;Matteo Aulicino,&nbsp;Stefanie Marek-Iannucci,&nbsp;Giovanna Manzi,&nbsp;Domenico Filomena,&nbsp;Marco Valerio Mariani,&nbsp;Lucia Ilaria Birtolo,&nbsp;Silvia Papa,&nbsp;Massimo Mancone,&nbsp;Viviana Maestrini,&nbsp;Roberto Badagliacca,&nbsp;Carmine Dario Vizza,&nbsp;Paolo Severino","doi":"10.1007/s40256-025-00770-9","DOIUrl":"10.1007/s40256-025-00770-9","url":null,"abstract":"<div><h3>Purpose</h3><p>Heart failure with reduced ejection fraction (HFrEF) represents a complex clinical syndrome requiring the timely initiation of disease-modifying therapies. However, the optimal timing for introducing these therapies in the hospital setting remains an area of investigation. This study aims to evaluate whether the early in-hospital initiation of sodium–glucose co-transporter 2 inhibitors (SGLT2i) facilitates the introduction of angiotensin receptor–neprilysin inhibitors (ARNI) during hospitalization and whether this strategy is associated with improved left ventricular systolic function at 6-month follow-up.</p><h3>Methods</h3><p>In this prospective, observational, single-centre study, consecutive patients with HFrEF were enrolled and divided into two groups on the basis of the timing of SGLT2i initiation: Group 1 (in-hospital) and Group 2 (post-discharge). The differences in terms of ARNI introduction within hospitalization were evaluated in the two groups. Changes in echocardiographic parameters (left ventricular ejection fraction [LVEF], left ventricular end-diastolic volume [LVEDV], left ventricular end-systolic volume [LVESV], <i>E</i>/<i>e</i>′ ratio) at 6-month follow up have been compared among patients treated with ARNI+SGLT2i and SGLT2i alone.</p><h3>Results</h3><p>A total of 285 patients were enrolled, 151 for G1 and 134 for G2. Early in-hospital use of SGLT2i was an independent predictor of ARNI initiation before discharge (odds ratio, OR: 3.31; 95% confidence intervals, CI 1.87–5.84; <i>p</i> &lt; 0.001). Among the 89 patients of G1 who completed 6 months of follow-up, early in-hospital therapy with SGLT2i and ARNI represents an independent significant predictor of LVEF &gt; 10% improvement, compared with those treated with SGLT2i alone (OR: 5.353; 95% CI 1.504–12.070; <i>p</i> &lt; 0.003).</p><h3>Conclusions</h3><p>Early in-hospital initiation of SGLT2i in patients with HFrEF is associated with a higher likelihood of in-hospital ARNI introduction and with significant improvements in left ventricular systolic function at 6-month follow-up.</p></div>","PeriodicalId":7652,"journal":{"name":"American Journal of Cardiovascular Drugs","volume":"26 2","pages":"205 - 214"},"PeriodicalIF":3.0,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12920402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145237570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authors’ Reply to Pang et al: “A Retrospective Cohort Study on Long-Term Outcomes of Ticagrelor Versus Clopidogrel After Retrograde Percutaneous Coronary Intervention for Chronic Total Occlusion”","authors":"Feihuang Han,&nbsp;Zehan Huang,&nbsp;Bin Zhang","doi":"10.1007/s40256-025-00769-2","DOIUrl":"10.1007/s40256-025-00769-2","url":null,"abstract":"","PeriodicalId":7652,"journal":{"name":"American Journal of Cardiovascular Drugs","volume":"26 1","pages":"123 - 125"},"PeriodicalIF":3.0,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145231349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Tirzepatide on Cardiovascular Outcomes","authors":"Jessica Huston,&nbsp;Dontia Orey,&nbsp;Andrew Ashchi,&nbsp;Andrea Ashchi Lachapelle,&nbsp;Ariana Genovese,&nbsp;Jenna Jackson,&nbsp;Ramsey Ashchi,&nbsp;Towfeeq Ashchi,&nbsp;Majdi Ashchi,&nbsp;David Sutton,&nbsp;Wasim Deeb,&nbsp;Rebecca F. Goldfaden","doi":"10.1007/s40256-025-00767-4","DOIUrl":"10.1007/s40256-025-00767-4","url":null,"abstract":"<div><p>Patients with type 2 diabetes mellitus and obesity have a higher risk of cardiovascular disease and major adverse cardiovascular events. It is important that medication options for these disease states are either cardioprotective or cardioneutral so that the health of the patient is not worsened. Medications in the glucagon-like peptide-1 receptor agonists class decrease cardiovascular risk in those at high or increased risk of cardiovascular events. This review presents and discusses the current clinical and scientific evidence pertaining to tirzepatide, a glucagon-like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor co-agonist.</p></div>","PeriodicalId":7652,"journal":{"name":"American Journal of Cardiovascular Drugs","volume":"26 2","pages":"157 - 163"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145197954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contemporary Antianginal Therapy","authors":"Sagar Patel,&nbsp;Vishal Patel,&nbsp;Mohammed Ayyad,&nbsp;Arthi Palani,&nbsp;Joseph Allencherril","doi":"10.1007/s40256-025-00766-5","DOIUrl":"10.1007/s40256-025-00766-5","url":null,"abstract":"<div><p>Stable angina management and pharmacotherapy varies widely despite the longstanding availability of several drug classes. We herein review current angina management strategies through the lens of optimal medical therapy (OMT), while highlighting emerging therapies and the growing clinical significance of coronary microvascular dysfunction (CMD). This narrative review synthesizes findings from existing research and key clinical trials to outline both established and evolving treatment approaches for chronic stable angina. Beta-blockers and calcium channel blockers remain the foundation of symptom management, while nitrates, ranolazine, ivabradine, and trimetazidine may be considered for refractory symptoms. Few novel pharmacologic therapies have emerged in recent decades, underscoring a critical need for innovation—particularly in the treatment of CMD, which is increasingly recognized as a distinct pathophysiologic entity requiring targeted therapy. Advances in invasive coronary function testing have improved diagnostic accuracy for CMD, yet consensus on optimal treatment remains elusive. Emerging interventional strategies and stem cell-based interventions show promise for patients with refractory angina who lack further revascularization options. The limited progress in novel pharmacologic development reinforces the need for ongoing research to refine therapeutic strategies for CMD and expand treatment options for patients with treatment-resistant angina.</p></div>","PeriodicalId":7652,"journal":{"name":"American Journal of Cardiovascular Drugs","volume":"26 2","pages":"137 - 155"},"PeriodicalIF":3.0,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12920388/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145147413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial","authors":"Xiaofan Yu,&nbsp;Jie Xu,&nbsp;Jiaoyu Cao,&nbsp;Qizhi Xu,&nbsp;Hongwu Chen,&nbsp;Dongbiao Yu,&nbsp;Xunxia Yao,&nbsp;Kaibing Chen,&nbsp;Likun Ma","doi":"10.1007/s40256-025-00764-7","DOIUrl":"10.1007/s40256-025-00764-7","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;p&gt;Nicotinamide adenine dinucleotide (NAD+) is a fundamental coenzyme that plays a crucial role in cellular energy metabolism and redox homeostasis. A deficiency in NAD+ has been associated with heart failure (HF), which often occurs in the advanced stages of cardiovascular diseases. While numerous studies have indicated that NAD+ supplementation may enhance cardiac bioenergetics and function in animal models, there is limited research investigating this potential effect in human patients. Therefore, this study aims to evaluate whether NAD+ treatment can lead to improved clinical outcomes for patients with HF due to ischemic cardiomyopathy (ICM).&lt;/p&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;p&gt;This single-center, prospective, randomized, placebo-controlled trial enrolled 180 adults diagnosed with ICM whose left ventricular ejection fraction (LVEF) was ≤ 45% and whose New York Heart Association (NYHA) grade was II–III. Participants were randomly assigned to receive either intravenous NAD⁺ (10 mg/day) or an equivalent placebo (5% glucose/normal saline) for a duration of 7 days, alongside guideline-directed medical therapy. The primary endpoint was the Change in LVEF at 1 month. Secondary endpoints included changes in N-terminal pro B-type natriuretic peptide (NT-proBNP) at 7 and 30 days; a composite of major adverse cardiac and cerebrovascular events (MACCE), which encompassed cardiac death, non-fatal myocardial infarction, stroke, and the first unplanned HF hospitalization within 6 months; and improvements in NYHA functional class.&lt;/p&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;At 1 month, the NAD+ group demonstrated a significantly greater improvement in LVEF compared to the placebo group (45.44 ± 8.55% vs. 42.44 ± 9.09%, &lt;i&gt;p =&lt;/i&gt; 0.024). A trend towards decreased NT-proBNP levels was observed in the NAD+ group at day 7 (1471.00 [828.00–2950.00]pg/mL vs. 2317.50 [1155.00–4752.50]pg/mL, &lt;i&gt;p&lt;/i&gt; = 0.102). The 6-month composite MACCE rate appeared lower among those receiving NAD+ treatment compared to the placebo group (14.6% vs. 24.7%, &lt;i&gt;p =&lt;/i&gt; 0.089), primarily driven by a trend toward fewer first unplanned HF hospitalizations (13.5% vs. 23.6%, &lt;i&gt;p =&lt;/i&gt; 0.078). Additionally, a greater proportion of patients in the NAD+ group demonstrated improvement in NYHA functional class at both 1 month (73.0% vs. 57.3%, &lt;i&gt;p =&lt;/i&gt; 0.088) and 6 months (53.9% vs. 39.3%, &lt;i&gt;p =&lt;/i&gt; 0.115). No significant differences were observed in structural parameters (left ventricular end-diastolic diameter, left ventricular end-diastolic volume, left atrial diameter).&lt;/p&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;p&gt;This study has confirmed that supplementation with NAD+ can enhance cardiac function in patients with from HF due to ICM, thereby affirming its beneficial impact on cardiac performance. Trends indicating reductions in NT-proBNP levels and composite clinical events (particularly HF hospitalization) and improvements in NYHA functional class were noted, suggesting potential broader clinical benefits. These f","PeriodicalId":7652,"journal":{"name":"American Journal of Cardiovascular Drugs","volume":"26 1","pages":"97 - 106"},"PeriodicalIF":3.0,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40256-025-00764-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145068795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}